Payment overview · 2025
General Payments
$128.78
6 reported records · 5 companies
Healthcare provider profile · identity verified
Thomas Vernon Messe, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PACE, FL · NPI 1366422784
Verified facts
What the public records show
CMS Open Payments records show Thomas Vernon Messe, M.D. received $128.78 in general payments during 2025 across 6 reported records.
Astellas Pharma US Inc accounted for 36.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $47.08 | 36.6% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $26.67 | 20.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.69 | 18.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.86 | 13.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.48 | 11.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $128.78 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $47.08 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $26.67 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.69 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.69 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 141 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 48 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
69 | 54 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
48 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
141 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 698 | 210 |
| Atorvastatin Calcium | Atorvastatin Calcium | 682 | 190 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 582 | 108 |
| Omeprazole | Omeprazole | 549 | 159 |
| Metoprolol Succinate | Metoprolol Succinate | 526 | 154 |
| Amlodipine Besylate | Amlodipine Besylate | 524 | 149 |
| Prednisone | Prednisone | 487 | 173 |
| Levothyroxine Sodium | Levothyroxine Sodium | 459 | 123 |
| Pantoprazole Sodium | Pantoprazole Sodium | 459 | 158 |
| Tramadol Hcl | Tramadol Hcl | 429 | 85 |
| Gabapentin | Gabapentin | 421 | 127 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 375 | 124 |
| Furosemide | Furosemide | 356 | 115 |
| Azithromycin | Azithromycin | 288 | 150 |
| Famotidine | Famotidine | 273 | 73 |
| Quetiapine Fumarate | Quetiapine Fumarate | 238 | 60 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 231 | 39 |
| Valsartan | Valsartan | 228 | 71 |
| Potassium Chloride | Potassium Chloride | 224 | 78 |
| Allopurinol | Allopurinol | 205 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 202 | 61 |
| Trazodone Hcl | Trazodone Hcl | 196 | 57 |
| Fluconazole | Fluconazole | 191 | 73 |
| Alprazolam | Alprazolam | 181 | 27 |
| Lisinopril | Lisinopril | 179 | 53 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 176 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 174 | 82 |
| Clonazepam | Clonazepam | 173 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 171 | 49 |
| Glimepiride | Glimepiride | 169 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 168 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 165 | 53 |
| Eliquis | Apixaban | 164 | 43 |
| Lorazepam | Lorazepam | 163 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 160 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 152 | 45 |
| Metformin Hcl | Metformin Hcl | 152 | 46 |
| Montelukast Sodium | Montelukast Sodium | 152 | 45 |
| Tizanidine Hcl | Tizanidine Hcl | 150 | 33 |
| Ozempic | Semaglutide | 141 | 30 |
| Amitriptyline Hcl | Amitriptyline Hcl | 139 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 137 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 136 | 42 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 126 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 125 | 25 |
| Sertraline Hcl | Sertraline Hcl | 123 | 32 |
| Buspirone Hcl | Buspirone Hcl | 122 | 33 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 122 | 52 |
| Carvedilol | Carvedilol | 118 | 34 |
| Amoxicillin | Amoxicillin | 116 | 63 |
| Cephalexin | Cephalexin | 116 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 36 |
| Methocarbamol | Methocarbamol | 114 | 23 |
| Baclofen | Baclofen | 113 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 103 | 25 |
| Pregabalin | Pregabalin | 100 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 98 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 96 | 37 |
| Doxycycline Hyclate | Doxycycline Hyclate | 91 | 45 |
| Trulicity | Dulaglutide | 91 | 23 |
| Temazepam | Temazepam | 88 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 87 | 23 |
| Simvastatin | Simvastatin | 83 | 26 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 78 | 40 |
| Celecoxib | Celecoxib | 76 | 28 |
| Oxybutynin Chloride | Oxybutynin Chloride | 76 | 22 |
| Promethazine Hcl | Promethazine Hcl | 76 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 74 | 41 |
| Jardiance | Empagliflozin | 73 | 20 |
| Cefdinir | Cefdinir | 71 | 38 |
| Methylprednisolone | Methylprednisolone | 71 | 48 |
| Januvia | Sitagliptin Phosphate | 70 | 23 |
| Clonidine Hcl | Clonidine Hcl | 69 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 23 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 69 | 54 |
| Propranolol Hcl | Propranolol Hcl | 67 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 65 | 21 |
| Nitroglycerin | Nitroglycerin | 64 | 34 |
| Dupixent Pen | Dupilumab | 61 | suppressed |
| Finasteride | Finasteride | 61 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 61 | 20 |
| Meloxicam | Meloxicam | 59 | 17 |
| Donepezil Hcl | Donepezil Hcl | 58 | 17 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 56 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 55 | 14 |
| Mirtazapine | Mirtazapine | 55 | 13 |
| Ibuprofen | Ibuprofen | 54 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 17 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 53 | 27 |
| Lidocaine | Lidocaine | 52 | 19 |
| Metformin Hcl Er | Metformin Hcl | 52 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 52 | suppressed |
| Atenolol | Atenolol | 51 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 30 |
| Meclizine Hcl | Meclizine Hcl | 51 | 23 |
| Fenofibrate | Fenofibrate | 50 | 15 |
| Topiramate | Topiramate | 49 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 48 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 12 |
| Ondansetron Odt | Ondansetron | 47 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 47 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 46 | 15 |
| Metronidazole | Metronidazole | 45 | 24 |
| Spironolactone | Spironolactone | 45 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 43 | 12 |
| Clotrimazole | Clotrimazole | 42 | 18 |
| Olanzapine | Olanzapine | 42 | 15 |
| Sucralfate | Sucralfate | 42 | 20 |
| Divalproex Sodium | Divalproex Sodium | 40 | suppressed |
| Novolog Flexpen | Insulin Aspart | 40 | 14 |
| Rizatriptan | Rizatriptan Benzoate | 40 | suppressed |
| Clonidine | Clonidine | 39 | suppressed |
| Primidone | Primidone | 37 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | 13 |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Levofloxacin | Levofloxacin | 35 | 24 |
| Acyclovir | Acyclovir | 34 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Ezetimibe | Ezetimibe | 34 | 13 |
| Nystatin | Nystatin | 34 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 32 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 32 | 13 |
| Glipizide | Glipizide | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 29 | suppressed |
| Bumetanide | Bumetanide | 28 | suppressed |
| Colchicine | Colchicine | 28 | 12 |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 27 | suppressed |
| Loperamide | Loperamide Hcl | 27 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 26 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 26 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Lactulose | Lactulose | 19 | 12 |
| Linzess | Linaclotide | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Butalbital-Acetaminophen | Butalbital/Acetaminophen | 18 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 17 | 17 |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 15 | 15 |
| Clindamycin Hcl | Clindamycin Hcl | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Indomethacin | Indomethacin | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Klor-Con 8 | Potassium Chloride | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Trulance | Plecanatide | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Tetracycline Hcl | Tetracycline Hcl | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Pentazocine-Naloxone Hcl | Pentazocine Hcl/Naloxone Hcl | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $128.78 · 6 records | Astellas Pharma US Inc | CAPLYTA, EVENITY, Ozempic, Rybelsus, TRELEGY ELLIPTA, Veozah | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error